Sarat Chandarlapaty
@saratchandarlapaty.bsky.social
Physician Scientist, Medical Oncologist, My lab studies therapy resistance in breast cancer.
Pinned
APOBEC3 mutagenesis drives therapy resistance in breast cancer
Nature Genetics - Analysis of a large cohort of metastatic breast cancer samples shows that APOBEC mutational signatures are enriched in post-treatment samples. APOBEC activity was also associated...
urldefense.com
Published online today - work from our team led by Avantika Gupta, revealing how APOBEC3 mutagenesis promotes resistance to several targeted therapies in breast cancer. Check it out!
urldefense.com/v3/__https:/...
urldefense.com/v3/__https:/...
Reposted by Sarat Chandarlapaty
Now online in Cancer Discovery @aacrjournals.bsky.social: Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding - by Wanyi Chen, @joshdragomd.bsky.social, @saratchandarlapaty.bsky.social, and colleagues doi.org/10.1158/2159... @mskcancercenter.bsky.social
November 10, 2025 at 6:15 PM
Now online in Cancer Discovery @aacrjournals.bsky.social: Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding - by Wanyi Chen, @joshdragomd.bsky.social, @saratchandarlapaty.bsky.social, and colleagues doi.org/10.1158/2159... @mskcancercenter.bsky.social
Reposted by Sarat Chandarlapaty
ADC resistance is likely heterogeneous, and the phenomena above may explain only a portion of cases. But these early clues can inform prospective trail efforts, as well as ADC sequencing strategies. There is much more to come!
November 10, 2025 at 4:55 PM
ADC resistance is likely heterogeneous, and the phenomena above may explain only a portion of cases. But these early clues can inform prospective trail efforts, as well as ADC sequencing strategies. There is much more to come!
Reposted by Sarat Chandarlapaty
In this manuscript, online today in Cancer Discovery, we investigate target-mediated resistance to ADCs, and propose ways to overcome it.
aacrjournals.org/cancerdiscov...
aacrjournals.org/cancerdiscov...
Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding
Abstract. T-DXd is clinically beneficial in HER2 positive and HER2 low metastatic breast cancer. However, therapeutic resistance emerges over time in most patients, with poorly defined resistance mech...
aacrjournals.org
November 10, 2025 at 4:55 PM
In this manuscript, online today in Cancer Discovery, we investigate target-mediated resistance to ADCs, and propose ways to overcome it.
aacrjournals.org/cancerdiscov...
aacrjournals.org/cancerdiscov...
Published online today - work led by Yanyan Cai: Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers | Science Translational Medicine www.science.org/doi/10.1126/...
Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers
NR2F2 modulates the ER cistrome, coregulator interactions, and chromatin accessibility to promote endocrine resistance in ER+ breast cancer.
www.science.org
June 4, 2025 at 6:51 PM
Published online today - work led by Yanyan Cai: Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers | Science Translational Medicine www.science.org/doi/10.1126/...
Reposted by Sarat Chandarlapaty
🚨 NEW in @natgenet.nature.com: MSK's Dr. Sarat Chandarlapaty and colleagues investigates how APOBEC3 #mutagenesis drives therapy resistance in #BreastCancer. Learn more: www.nature.com/articles/s41...
May 16, 2025 at 5:10 PM
🚨 NEW in @natgenet.nature.com: MSK's Dr. Sarat Chandarlapaty and colleagues investigates how APOBEC3 #mutagenesis drives therapy resistance in #BreastCancer. Learn more: www.nature.com/articles/s41...
Reposted by Sarat Chandarlapaty
So excited to share our latest work with @saratchandarlapaty.bsky.social, Antonio Marra, Andrea Gazzo @mskcancercenter.bsky.social out today in @natgenet.nature.com! We uncover the function and mechanism of APOBEC3-driven therapy resistance in breast cancer. 🧵 1/
www.nature.com/articles/s41...
www.nature.com/articles/s41...
APOBEC3 mutagenesis drives therapy resistance in breast cancer - Nature Genetics
Analysis of a large cohort of metastatic breast cancer samples shows that APOBEC mutational signatures are enriched in post-treatment samples. APOBEC activity was also associated with mutations known ...
www.nature.com
May 16, 2025 at 12:01 PM
So excited to share our latest work with @saratchandarlapaty.bsky.social, Antonio Marra, Andrea Gazzo @mskcancercenter.bsky.social out today in @natgenet.nature.com! We uncover the function and mechanism of APOBEC3-driven therapy resistance in breast cancer. 🧵 1/
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Published online today - work from our team led by Avantika Gupta, revealing how APOBEC3 mutagenesis promotes resistance to several targeted therapies in breast cancer. Check it out!
urldefense.com/v3/__https:/...
urldefense.com/v3/__https:/...
APOBEC3 mutagenesis drives therapy resistance in breast cancer
Nature Genetics - Analysis of a large cohort of metastatic breast cancer samples shows that APOBEC mutational signatures are enriched in post-treatment samples. APOBEC activity was also associated...
urldefense.com
May 16, 2025 at 11:33 AM
Published online today - work from our team led by Avantika Gupta, revealing how APOBEC3 mutagenesis promotes resistance to several targeted therapies in breast cancer. Check it out!
urldefense.com/v3/__https:/...
urldefense.com/v3/__https:/...
Reposted by Sarat Chandarlapaty
@saratchandarlapaty.bsky.social expertly summarizing our work on how underlying genomic instability in breast cancer leads to therapy resistance leaving with key ideas on how we might target them! Come see me expand on the role of APOBEC3 mutagenesis in these processes tomorrow morning at #AACR25!
April 28, 2025 at 3:51 PM
@saratchandarlapaty.bsky.social expertly summarizing our work on how underlying genomic instability in breast cancer leads to therapy resistance leaving with key ideas on how we might target them! Come see me expand on the role of APOBEC3 mutagenesis in these processes tomorrow morning at #AACR25!
Reposted by Sarat Chandarlapaty
A hugely collaborative team effort under the mentorship of @saratchandarlapaty.bsky.social @mskcancercenter.bsky.social
December 13, 2024 at 1:14 AM
A hugely collaborative team effort under the mentorship of @saratchandarlapaty.bsky.social @mskcancercenter.bsky.social
Fabulous plenary from Dr. Pedram Razavi #sabcs2024 on robust and innovative ai models to separate cdk4/6i responders from non-responders.
December 13, 2024 at 5:22 PM
Fabulous plenary from Dr. Pedram Razavi #sabcs2024 on robust and innovative ai models to separate cdk4/6i responders from non-responders.
Fantastic presentation #SABCS by @avantikagupta.bsky.social on apobec3 in breast cancer. Demonstrating the role of this process in promoting therapy resistance.
December 12, 2024 at 5:51 PM
Fantastic presentation #SABCS by @avantikagupta.bsky.social on apobec3 in breast cancer. Demonstrating the role of this process in promoting therapy resistance.
Reposted by Sarat Chandarlapaty
Congratulations to @caiy0219.bsky.social for an excellent poster presentation today! 👏🏽
Also, so happy to be reunited with @reikudo.bsky.social to represent the translational team in @saratchandarlapaty.bsky.social’s lab at #SABCS2024!
Also, so happy to be reunited with @reikudo.bsky.social to represent the translational team in @saratchandarlapaty.bsky.social’s lab at #SABCS2024!
December 12, 2024 at 3:47 AM
Congratulations to @caiy0219.bsky.social for an excellent poster presentation today! 👏🏽
Also, so happy to be reunited with @reikudo.bsky.social to represent the translational team in @saratchandarlapaty.bsky.social’s lab at #SABCS2024!
Also, so happy to be reunited with @reikudo.bsky.social to represent the translational team in @saratchandarlapaty.bsky.social’s lab at #SABCS2024!
Super plenary from Komal Jhaveri on imlunestrant #sabcs Congrats to her and the Ember-3 trial authors for developing this SERD (and combo with Abema)
December 11, 2024 at 3:34 PM
Super plenary from Komal Jhaveri on imlunestrant #sabcs Congrats to her and the Ember-3 trial authors for developing this SERD (and combo with Abema)
Reposted by Sarat Chandarlapaty
NEW #Oncology:
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
Gupta et al. demonstrate that high EGFR expression mediates resistance to HER2 antibody
drug conjugates (ADCs) including trastuzumab deruxtecan (T-DXd) by limiting HER2/ADC
internalization. The additi...
www.cell.com
November 12, 2024 at 12:33 PM
NEW #Oncology:
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...